• David L. Bartlett
Part of the Medical Intelligence Unit book series (MIU.LANDES)


Somatostatin and its analogues have diverse indications in the work—up and treatment of the cancer patient. These range from diagnosis and localization with octreotide scintigraphy to decreasing postoperative complications following pancreaticoduodenectomy for pancreatic cancer. In addition, somatostatin has direct inhibitory activity on the proliferation of some human cancer cells, and has been utilized as antineoplastic therapy.1 Despite its broad spectrum of activity in the cancer patient and its diverse inhibitory properties, the effect of somatostatin on cancer cachexia and protein metabolism in the cancer patient has not been defined. The purpose of this chapter is to provide a background on the properties and function of somatostatin in the cancer patient, and to discuss the effect somatostatin may have on metabolism in the tumor-bearing host. Experimental data from animal models will be presented which support the use of somatostatin anologues as a means for inhibiting hormonal secretion in the tumor-bearing host. This may have a significant impact on cancer cachexia.


Growth Hormone Irritable Bowel Syndrome Glucagon Secretion Cancer Cachexia Islet Cell Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mozell EJ, Woltering EA, O’Dorisio TM. Non-endocrine applications of somatostatin and octreotide acetate:facts and flights of fancy. Dis Mon 1991; 37: 749–848.PubMedCrossRefGoogle Scholar
  2. 2.
    Krulich L, Dhariwal A, McCann S. Stimulatory and inhibitory effects of purified hyothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968; 83: 783–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Brazeau P, Vale W, Burgus R et al. Hypothalamic peptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Hellman B, Lernmark A. Inhibition of the in vitro secretion of insulin by an extract of pancreatic alpha-1 cells. Endocrinology 1969; 84: 1484–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Reichlin SR. Somatostatin. N Engl J Med 1983; 309 (24): 1495–501.PubMedCrossRefGoogle Scholar
  6. 6.
    Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hSSTR1–5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994; 605–12.Google Scholar
  7. 7.
    Polak JM, Bloom SR. Somatostatin localization in tissues. Scand J Gastroenterol 1986; 21 (suppl 119): 11–21.CrossRefGoogle Scholar
  8. 8.
    Harris AG. Somatostatin and somatostatin analogues:pharmacokinetics and pharmacodynamic effects. Gut 1994; 35: S1–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Veber DF, Freidinger RM, Schwenk-Perlow D et al. A potent cyclic hexapeptide analogue of somatostatin. Nature 1981; 292: 55–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988; 48: 6977–85.PubMedGoogle Scholar
  11. 11.
    Bauer W, Briner U, Doepfner W et al. SMS 201–995:a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Davies RR, Turner SJ, Alberti KG, Johston DG. Somatostatin analogues in diabetes mellitus. Diabet Med 1989; 6 (2): 103–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Tyden G, Samnegard H, Thulin L. Treatment of bleeding esophageal varices with somatostatin. N Engl J Med 1978; 299: 1466–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Kayassey L, Keller V, Gyr K, Stalder GA, Wall M. Somatostatin and cimetidine in peptic ulcer hemorrhage:a randomized controlled trial. Lancet 1980; 1: 844–6.CrossRefGoogle Scholar
  15. 15.
    Pederzoli P, Bassi C, Falconi M et al. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with somatostatin, glucagon, or calcitonin. Surg Gynecol Obstet 1986; 90: 1405–11.Google Scholar
  16. 16.
    Limburg B, Kommerfell B. Treatment of acute pancreatitis with somatostatin. N Engl J Med 1980; 303: 284–7.Google Scholar
  17. 17.
    Hopman WPM, Wolberink RGJ, Lamers CBHW, VanTongeren JHM. Treatment of the dumping syndrome with the somatostatin analogue SMS 201–995. Ann Surg 1988; 207: 155–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Talley NJ, Turner I, Middleton WR. Somatostatin and symptomatic relief of irritable bowel syndrome. Lancet 1987; 2: 1114–7.Google Scholar
  19. 19.
    Nubiola-Calonce P, Sancho J, Segura M et al. Blind evaluation of the effect of octreotide (SMS 201–995), a somatostatin analogue, on small-bowel fistula output. Lancet 1987; 2: 672–4.CrossRefGoogle Scholar
  20. 20.
    Weber G, Klughardt G, Neidhardt M et al. Treatment of psoriasis with somatostatin. Arch Dermatol Res 1982; 272: 31–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Chrubasik J, Moynadier J, Scherpereel P, Wunsch E. The effect of epidural somatostatin on post-operative pain. Anesth Analgesia 1985; 64: 1085–8.CrossRefGoogle Scholar
  22. 22.
    Hoeldtke R, O’Dorisio T, Boden G. Treatment of autonomic neuropathy with a somatostatin analog, SMS 201–995. Lancet 1986; 2: 602–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev 1991; 12 (4): 450–82.CrossRefGoogle Scholar
  25. 25.
    Canivet B, Le Cam A, Freychet P. Somatostatin: lack of effect of cyclic AMP release and amino acid transport in isolated rat hepatocytes. Diabetes Metab 1979; 5: 17–9.Google Scholar
  26. 26.
    Katz MD, Erstad BL. Octreotide, a new somatostatin analogue. Clin Pharm 1989; 8: 255–73.PubMedGoogle Scholar
  27. 27.
    Johnston DG, Davies RR, Turner SJ. Effects of somatostatin and SMS 201–995 on carbohydrate metabolism in normal man. Scand J Gastroenterol 1986; 21 (suppl 119): 158–65.CrossRefGoogle Scholar
  28. 28.
    Owyang C. Octreotide in gastrointestinal motility disorders. Gut 1994; 35: S11–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Johnson FE, LaRegina MC, Devine JE, Hudd C. Effect of chronically administered somatostatin on the nude mouse. J Surg Res 1986; 40: 346–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Bartlett DL, Torosian MH. Biochemical and biological effects of somatostatin therapy on tumor growth and host metabolism. Int J Oncol. 1995; (in press).Google Scholar
  31. 31.
    Bartlett DL, Stein TP, Torosian MH. Effect of growth hormone and protein intake on tumor growth and host cachexia. Surgery 1995; 117 (3): 260–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Unger RH. Glucagon and the insulin:glucagon ratio in diabetes and other catabolic illnesses. Diabetes 1971; 20: 834–8.PubMedGoogle Scholar
  33. 33.
    Wolfe BM, Culebras JM, Aoki TT et al. The effects of glucagon on protein metabolism in normal man. Surgery 1979; 86 (2): 248–57.PubMedGoogle Scholar
  34. 34.
    Unger RH, Orci L. Glucagon and the A cell: Physiology and Pathophysiology (first of two parts). N Engl J Med 1981; 304 (25): 1518–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (second of two parts). N Engl J Med 1981; 304 (26): 1575–80.PubMedCrossRefGoogle Scholar
  36. 36.
    Aoki TT, Muller WA, Brennan MF,-Cahill GF. Effect of glucagon on amino acid and nitrogen metabolism in fasting man. Metabolism 1974; 23 (9): 805–14.PubMedCrossRefGoogle Scholar
  37. 37.
    Raskin P, Unger RH. Effects of exogenous hyperglucagonemia in insulin-treated diabetics. Diabetes 1977; 26: 1034–9.PubMedGoogle Scholar
  38. Bloom SR, Polak JM. Glucagonoma syndrome. [Review]. Am J Med 1987; 82:25–36.Google Scholar
  39. 39.
    Pacy PJ, Cheng KN, Ford GC, Halliday D. Influence of glucagon on protein and leucine metabolism:a study in fasting man with induced insulin resistance. Br J Surg 1990; 77: 791–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Preedy VR, Garlick PJ. The effect of glucagon administration on protein synthesis in skeletal muscles, heart and liver in vivo. Biochem J 1985; 228: 575–81.PubMedGoogle Scholar
  41. 41.
    Nair KS, Halliday D, Matthews DE, Welle SL. Hyperglucagonemia during insulin deficiency accelerates protein catabolism. Am J Physiol 1987; 253: E208–13.PubMedGoogle Scholar
  42. 42.
    Chance WT, vanLammeren FM, Chen MH, Murphy RF, Joffe SN, Fischer JE. Alteration in plasma levels of insulin and glucagon associated with cancer anorexia. Surg Forum 1983; 34: 441–3.Google Scholar
  43. 43.
    Tessitore L, Costelli P, Baccino FM. Humoral mediation for cachexia in tumour-bearing rats. Br J Cancer 1993; 67: 15–23.PubMedCrossRefGoogle Scholar
  44. 44.
    Knapp ML, al-Sheibani S, Riches PG, Hanham IW, Phillips RH. Hormonal factors associated with weight loss in patients with advanced breast cancer. Ann Clin Biochem 1991; 28: 480–6.PubMedGoogle Scholar
  45. 45.
    Bartlett DL, Charland SL, Torosian MH. Reversal of tumor-associated hyperglucagonemia as treatment for cancer cachexia. Surgery1995; 118(1):87–97.Google Scholar
  46. 46.
    Chance WT, Muggia-Sullam M, Chen MH, Murphy RF, Fischer JE. Reversal of tumor-induced biochemical abnormalities by insulin treatment in rats. J Natl Cancer Inst 1986; 77: 497–503.PubMedGoogle Scholar
  47. 47.
    Tessitore L, Costelli P, Baccino FM. Pharmacological interference with tissue hypercatabolism in tumour-bearing rats. Biochem J 1994; 299: 71–8.PubMedGoogle Scholar
  48. 48.
    Heslin MJ, Newman E, Wolf RF, Pisters PWT, Brennan MF. Effect of systemic hyperinsulinemia in cancer patients. Cancer Res 1992; 52: 3845–50.PubMedGoogle Scholar
  49. 49.
    Svaninger G, Drott C, Lundholm K. Role of insulin in development of cancer cachexia in nongrowing sarcoma-bearing mice: special reference to muscle wasting. JNCI 1987; 78: 943–50.PubMedGoogle Scholar
  50. 50.
    Muller WA, Faloona GR, Unger RH. The effect of the composition of the antecedent diet upon glucagon and insulin secretion. N Engl J Med 1971; 285: 1450–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Shaw JH, Wolfe RR. Metabolic intervention in surgical patients. An assessment of the effect of somatostatin, ranitidine, naloxone, diclophenac, dipyridamole, or salbutamol infusion on energy and protein kinetics in surgical patients using stable and radioisotopes. Ann Surg 1988; 207: 274–82.PubMedCrossRefGoogle Scholar
  52. 52.
    Bartlett DL, Charland S, Torosian MH. Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer 1994; 73: 1499–504.PubMedCrossRefGoogle Scholar
  53. 53.
    Popp MB, Kirkemo A, Morrison SD, Brennan MF. Tumor and host carcass changes during total parenteral nutrition in an anorectic rat-tumor system. Ann Surg 1984; 199: 205–10.PubMedCrossRefGoogle Scholar
  54. 54.
    Torosian MH, Williams N, Nguyen H. Effect of nutrition on tumor growth and cell cycle kinetics. J Parent Ent Nutr 1989; 13 (7S): 33–8.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • David L. Bartlett

There are no affiliations available

Personalised recommendations